ELASMOGEN
discovering and developing soloMERs for the treatment of auto-immune mediated, inflammatory diseases
To discuss Elasmogen’s press release and news flow please contact info@elasmogen.com
Date: 16th September 2022 Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen exclusive access to Soteria® and Phloral® technologies for oral colonic delivery of therapeutic proteins, deriving from Elasmogen’s soloMER™ platform, for an undisclosed target for treatment of Crohn’s disease and ulcerative […]
Description Elasmogen Ltd is a multi-award-winning next generation therapeutic biologics company discovering and developing soloMERs™ for the treatment of oncology and autoimmune mediated inflammatory diseases. Currently located on the Foresterhill Health Campus, Aberdeen, and part of the city’s thriving biologics cluster, Elasmogen will be moving into the £40 million state-of-the-art Aberdeen life sciences BioHub also […]
Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. The multi-million-pound investment will enable Aberdeen-based Elasmogen […]
MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16. The new VNARs will not be immediately available as a treatment in people, but they […]
Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship (FLF) Scheme. Dr Obinna Ubah, heads up Scottish biotechnology company Elasmogen Ltd’s auto-immune and anti-inflammation research efforts, and has received a £2 M research award of which £1.57 M is a grant […]
At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland: Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMERTM biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially […]
New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland: Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a significant development in its comprehensive intellectual property position as two new patent families go to grant in multiple territories. These […]
New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020: Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new grants worth £374,000 to support programs for COVID-19 and oncology. In April 2020 Elasmogen secured £143,000 from Scottish Government to use their drug discovery platform to accelerate […]
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]
29th April 2020; Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) are to collaborate with the University of Aberdeen as a partner on a Scottish Government research award of almost £1 M to tackle COVID-19. Current diagnostic testing for COVID-19 so called RT-PCR for infectious agents, whilst accurate is complex to perform, suited to centralised laboratories, takes […]